肝源性糖尿病发病机制研究进展*

doi:10.3969/j.issn.1672-5069.2016.03.034

Abstract

Abstract: Hepatogenous diabetes（HD） is secondary to chronic liver injury. Epidemiological studies in recent years have showed that insulin resistance is a risk factor of developing HD. However，the specific mechanism for HD occurrence remains unclear，and understanding the pathogenesis of HD can help to improve the management and prevention of HD. This article mainly reviewed the effects of insulin secretion and metabolic disturbance，hepatitis virus infection，liver fibrosis and liver cirrhosis，the involvement of insulin-like growth factor-1，tumor necrosis factor-α，free fatty acids，adipocyte factors including leptin and adiponectin，and other aspects of the latest findings.

Key words: Hepatogenous diabetes, Pathogenesis, Insulin resistance

Hu Qingling,Huang Yaxiong,Xie Yuanlin. Advances in the pathogenesis of hepatogenous diabetes[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 377-380.

References

[1] Qiu NC，Zhang Q，Song X，et al. Impact of the hepatic branch of the vagus and Roux-en-Y gastric bypass on the hypoglycemic effect and glucagon-like petide-1 in rats with type 2 diabetes mellitus. J Surg Res，2014，191（1）:123-129.
[2] Porepa L，Ray JG，Sanchez-Romeu P，et al. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ，2010，182（11）:E526-531.
[3] Han J，Mclane B，Kim EH，et al. Remission of diabetes by insulin gene therapy using a hepatocyte-specific and glucose-responsive synthetic promoter. Mol Ther，2011，19（3）:470-478.
[4] Kawaguchi T，Taniguchi E，Itou M，et al. Insulin resistance and chronic liver disease. World J Hepatol，2011，3（5）:99-107.
[5] Jenks SJ，Conway BR，Hor TJ，et al. Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with type 2 diabetes. Diabet Med， 2014，31（9）:1039-1046.
[6] Yang BT，Dayeh TA，Volkov PA，et al. Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes. Mol Endocrinol，2012，26（7）:1203-1212.
[7] Jacobson IM，Cacoub P，Dal Maso L，et al. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol，2010，8（12）:1017-1029.
[8] Sanlioglu AD，Altunbas HA，Balci MK，et al. Insulin gene therapy from design to β cell generation. Expert Rev Mol Med， 2012，14:e18.
[9] Winhofer Y，Krssák M，Wolf P，et al. Hepatic rather than cardiac steatosis relates to glucose intolerance in women with prior gestational diabetes. PloS One，2014，9（3）:e91607.
[10] Soverini V，Persico M，Bugianesi E，et al. HBV and HCV infection in type 2 diabetes mellitus:a survey in three diabetes units in different Italian areas. Acta Diabetol，2011，48（4）:337-343.
[11] Papatheodoridis GV，Manolakopoulos S，Margariti A， et al. The usefulness of transient elast ography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat，2014，21:517-524.
[12] Pazhanivel M，Jayanthi V. Diabetes mellitus and cirrhosis liver. Minerva Gastroenterol Dietol，2010，56（1）:7-11.
[13] Naing C，Mak JW，Ahmed SI，et al. Relationship between hepatitis C virus infection and type 2 diabetes mellitus:meta- analysis. World J Gastroenterol，2012，18（14）:1642-1651.
[14] Trpkovic A，Stokic E，Rada k，et al. Chronic hepatitis C infection，insulin resistance and vascular disease. Curr Pharm Des，2010，16（34）:3823-3829.
[15] Hung CH，Lee CM，Lu SN. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther，2011，9（5）:525－533．
[16] Croker BA，Kiu H，Pellegrini M，et al. IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3. Immunol Cell Biol，2012，90（1）:124-129.
[17] Bluyssen HA，Rastmanesh MM，Tiburgs C，et al. IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. Am J Physiol Cell Physiol，2010，299（2）:C354-362.
[18] Zhang P，Zhao Y，Zhu X，et al. Cross-talk between phosphor-STAT3 and PLC gammal play a critical role in colorectal tumorigenesis. Mol Cancer Res，2011，9（10）:1418-1428.
[19] Zauli G，Toffoli B，di Iasio MG，et al. Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes. Diabetes， 2010，59（5）:1261-1265.
[20] Feng X，Tang H，Leng J，et al. Suppressors of cytokine signaling （SOCS） and type2 diabetes. Mol Biol Rep，2014，41（4）: 2265-2274.
[21] Harith HH，Morris MJ，Kavurma MM. On the trail of obesity and diabetes. Trends Endocrin Metab，2013，24（11）:578-587.
[22] Tamiya T，Kashiwagi I，Takahashi R，et al. Suppressors of cytokine signaling （SOCS） proteins and JAK/STAT pathways:regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscl Throm Vasc Biol， 2011，31（5）:980-985.
[23] Hsieh PS，Hsieh YJ. Impact of liver diseases on the development of type 2 diabetes mellitus. World J Gastroenterol， 2011，17（48）:5240-5245.
[24] Kuroda T，Hirooka M，Koizumi M，et al. Pancreatic congestion in liver cirrhosis correlates with impaired insulin secretion. J Gastroenterol，2015，50（6）:683-693.
[25] Goswami A，Bhargava N，Dadhich S，et al. Insulin resistance in euglycemic cirrhosis. Ann Gastroenterol，2014，27（3）:237-243.
[26] Bhattacharya S，Bank S，Maiti S，et al. The control of hyperhlycemia by estriol and progesterone in alloxan induced type Ⅰ diabetes mellitus mice model through hepatic insulin synthesis. Int J Biamed Sci，2014，10（1）:5-15.
[27] Wang X，Bao W，Liu J，et al. Inflammatory markers and risk of type 2 diabetes:a systematic review and meta-analysis. Diabetes Care， 2013，36:166-175．
[28] Pal S，Polyak SJ，Bano N，et al. Hepatitis C virus induces oxidative stress，DNA damage and modulates the DNA repair enzyme NEILl. J Gastroenterol Hepatol，2010，25（3）:627-634.
[29] Gonzalez Y，Herrera MT，Soldevila G，et al. High glucose concentrations induce TNF-α production through the down regulation of CD33 in primary human monocyte. BMC Immunol，2012，13:19.
[30] Daniele G，Guardado Mendoza R，Winnier D，et al. The inflammatory status score including IL-6，TNF-α，osteopontin，fractalkine，MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol，2014，51（1）:123-131.
[31] Rigamonti AE，Agosti F，De Col A，et al. Severely obese adolescents and adults exhibit a different association of circulating levels of adipokines and leukocyte expression of the related receptors with insulin resistance. Int J Endocrinol，2013，2013:565697.
[32] Sun X，Han F，Yi J，et al. Effect of aspirin on the expression of hepatocyte NF-κB and serum TNF-α in streptozotocin- induced type 2 diabetic rats. J Korean Med Sci，2011，26（6）:765-770.
[33] Kleinsteuber K，Heesch K，Schattling S，et al. SOCS3 promotes interleukin-17 expression of human T cells. Blood，2012，120（22）:4374-4382.
[34] Whitmarsh RJ，Gray CM，Gregg B，et al. A critical role for SOCS3 in innate resistance to Toxoplasma gondii. Cell Host Microbe，2011，10（3）:224-236.
[35] Montonen J，Drogan D，Joost HG，et al. Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes. Eur J epidemiol，2011，26（1）:29-38.
[36] Kadowaki T，Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev，2005，26（3）:439-451.
[37] Wang F，Liu J，Lv Z. Association of Helicobacter pylori infection with diabetes mellitus and diabetic nephropathy:a meta-analysis of 39 studies involveing more than 20，000 participants. Scand J Infect Dis，2013，45（12）:930-938.
[38] Jeon CY，Haan MN，Cheng C，et al. Helicobacter pylori infection is associated with an increased rate of diabetes. Diabetes care， 2012，35（3）:520-525.

Advances in the pathogenesis of hepatogenous diabetes

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Shuai, Yang Changqing.. Pathogenesis and risk factors of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 761-764.
[2]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[3]	Liang Jubo, Miao Qi, Ma Xiong.. Diagnosis and treatment of cholangiocytic cholestasis [J]. Journal of Practical Hepatology, 2019, 22(6): 941-943.
[4]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[5]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[6]	Cui Ruibing, Yan Ming.. Etiology of ascites:what’s going on [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 657-660.
[7]	Li Yue, Ding Huiguo.. Current diagnosis and treatment of chylous ascites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 665-668.
[8]	Ge Jianxiang, Sun Yezi, Zhao Yun.. Application of entecavir in the treatment of patients with HBV-related cirrhosis complicated by hepatogenous diabetes and its influence on indexes of glucose metabolism [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 677-680.
[9]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.
[10]	Chi Zhaochun. Pathogenesis of nonalcoholic steatohepatitis and cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 166-169.
[11]	Chu Zhe, Chen Xue, Ma Li, et al. Application of health education by item-by-item learning in patients withhepatogenous diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 291-292.
[12]	Xin Fengzhi, Cao Haixia, Fan Jiangao. Glucagon-like peptide-1 in melioration of non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 313-316.
[13]	Xu Yan, Shi Cuicui, Fan Jiangao. What role the nonalcoholic fatty liver disease play in carcinogenesis of colorectal cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 149-152.
[14]	Xing Ying, Li Yali, Zheng Rongjiong. Effects of liraglutide on insulin resistance in rats with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 668-671.
[15]	Zhang Tingting, Yang Yan, Kang Yaojie. Efficacy of biphasic insulin aspart 50 in management of patients with hepatogenic diabetes [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 732-735.